- Previous Close
0.9300 - Open
0.9300 - Bid 0.9400 x 800000
- Ask 1.1500 x 600000
- Day's Range
0.9300 - 0.9400 - 52 Week Range
0.6550 - 1.2600 - Volume
380 - Avg. Volume
89 - Market Cap (intraday)
1.896B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
4.95 - EPS (TTM)
0.1900 - Earnings Date Aug 27, 2024 - Sep 2, 2024
- Forward Dividend & Yield 0.05 (5.55%)
- Ex-Dividend Date Jul 2, 2024
- 1y Target Est
--
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules. It also provides intermediate products, such as 6-aminopenicillanic acid, tert-octylammonium clavulanate, anhydrous sodium carbonate sterile, and penicillin G potassium first crystal. In addition, the company manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products, as well as offers management services. It has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
www.tul.com.cn15,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: UNJ.F
Performance Overview: UNJ.F
Trailing total returns as of 6/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UNJ.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UNJ.F
Valuation Measures
Market Cap
1.88B
Enterprise Value
1.52B
Trailing P/E
4.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.96
Price/Book (mrq)
1.03
Enterprise Value/Revenue
0.86
Enterprise Value/EBITDA
2.99
Financial Highlights
Profitability and Income Statement
Profit Margin
19.66%
Return on Assets (ttm)
9.90%
Return on Equity (ttm)
23.13%
Revenue (ttm)
13.74B
Net Income Avi to Common (ttm)
2.7B
Diluted EPS (ttm)
0.1900
Balance Sheet and Cash Flow
Total Cash (mrq)
4.26B
Total Debt/Equity (mrq)
11.80%
Levered Free Cash Flow (ttm)
187.24M